PharmTech LCGC Sciex Webinar 11.10
|Articles|February 10, 2010

LCGC Europe eNews

  • LCGC Europe eNews-02-05-2010
  • Volume 0
  • Issue 0

Joint venture forms new mass spectrometry company

AB SCIEX has been launched as a new company dedicated to life science analytical technologies. The new company is formed from the combination of the two halves of the AB SCIEX mass spectrometry joint venture.

AB SCIEX has been launched as a new company dedicated to life science analytical technologies. The new company is formed from the combination of the two halves of the AB SCIEX mass spectrometry joint venture.

“This integrated company will be able to shape the future of mass spectrometry in ways far greater than what we have already achieved,” said Laura Lauman, the company’s president, in a statement. According to Lauman, bringing the former joint venture together will enable the company to “keep pace with the dynamic needs of the life science industry.”

The company provides instrumentation, software and services used in a number of life science applications, including drug discovery and development, disease studies and food and environmental safety. These include integrated LC–MS–MS platforms for small molecule analysis, contaminant identification and biomarker validation, as well as MALDI TOF/TOF systems for protein biomarker discovery.

For more information about the company go to www.absciex.com

Articles in this issue


Related to this article

Best of the Week: From Cancer Diagnostics to Smarter LC Method Development
This week, Chromatography Online’s coverage spanned lipidomics-based early cancer detection, career paths in separation science, machine learning and uncertainty-driven approaches to LC method development, new EU wastewater rules for pharmaceutical micropollutants, automated Separation Quality Factor (SQF) evaluation in chromatography data systems, and solutions to GLP-1 peptide analysis challenges.